Avalon GloboCare Corp (ALBT): Still shorting? ....Thanks!!!

Play Episode

4min

Proactive - Interviews for investors

Opioid-Free pain relief: AFT’s global expansion strategy

AFT Pharmaceuticals Ltd Managing Director Dr Hartley Atkinson talked with Proactive at the AIM's Small and Midcap Conference about the company's unique approach to drug development, its expanding global footprint, and what lies ahead in 2025. AFT Pharmaceuticals is focused on creating pharmaceuticals "with a difference," targeting unmet needs and reducing reliance on opioids. “We don’t sell anything we don’t believe in,” said Dr Atkinson, highlighting the importance of alternatives to opioid treatments. One of the company’s key analgesic products helps avoid opioid use — a particularly timely innovation in light of the global opioid crisis. Dr Atkinson discussed the company’s core markets, with a strong presence in New Zealand and Australia, generating approximately 150 million in revenue. AFT also maintains operations in Asia and now exports to around 80 countries. The company has experienced sustained growth, having quadrupled in size over the past decade and doubled in the last five years. AFT has established six new affiliates across regions including Singapore, Hong Kong, South Africa, Canada, the UK, and Europe. Looking ahead, the company plans several product launches across Australia and New Zealand and anticipates five drug launches in China — the world’s second-largest pharmaceutical market. “For us, that’s going to be an interesting journey,” Atkinson added. #AFTPharmaceuticals #OpioidAlternatives #PharmaceuticalInnovation #ChinaPharma #DrugDevelopment #HealthcareGrowth #ASXStocks #BiotechInvesting #GlobalHealthcare #PharmaExpansion

Proactive - Interviews for investors

Acusensus talks global expansion and growth drivers

Acusensus Ltd Managing Director talked with Proactive at AIM's Small and Midcap Conference about the company’s progress in road safety technology, its global expansion, and the upcoming launch of a new product line aimed at road worker protection. Alex Jannink, Managing Director and Co-founder of Acusensus, explained how the company pioneered enforcement cameras targeting behaviours like mobile phone use and seatbelt compliance. “We supply these automated enforcement cameras...and we receive a fixed monthly fee essentially for those services,” he said, outlining the company's outsourced business model under long-term government contracts. While 93% of revenues currently come from Australia, Jannink confirmed growth is underway internationally, with active customers in the United States and United Kingdom. Acusensus has also secured a nationwide speed enforcement contract in New Zealand, expected to contribute significantly from the next financial year. Jannink highlighted the broader social mission behind the business: “The whole goal of the company is to change behaviours and to save lives.” He pointed to strong behavioural impacts from previous deployments, including a six-fold drop in mobile phone use and a 21% reduction in road fatalities in New South Wales. A new road worker safety product line is also in development and, according to Jannink, “can be as large as the enforcement business.” #Acusensus #RoadSafety #AItechnology #TrafficEnforcement #DriverSafety #ASXStocks #GovernmentContracts #InfrastructureSafety #SmartCameras #RoadWorkerProtection #AutonomousTech #InvestSmart #PublicSafetyTech

Proactive - Interviews for investors

CleanSpace eyes 30% growth, EBITDA breakeven

CleanSpace Holdings Ltd CEO Gabrielle O’Carroll talked with Proactive about AIM's Small and Midcap Conference about the company’s growth trajectory and product innovation in powered air purifying respirators (PAPRs). CleanSpace was founded in 2009, based on an innovation developed during the SARS epidemic. The company's differentiator is its lightweight, head-mounted respirators that contrast with the bulkier waist-mounted models commonly available in the industrial market. “We are steadily approaching that breakeven EBITDA, profitable EBITDA position, which is our goal,” O’Carroll said. O’Carroll explained that CleanSpace's respirators are well suited for industrial sectors like mining, infrastructure, and petrochemicals. The products are marketed in key regions including the United States, Western Europe, and Australia. The company has 52 employees and recorded AU$9.2 million in revenue in the first half, up 26% year-over-year. CleanSpace is targeting annual revenue growth of 25–30% and expects to achieve positive EBITDA soon. To drive this, the company is focused on raising brand awareness, engaging directly with end users, and supporting occupational hygienists and safety managers. CleanSpace is also investing in R&D to support future product launches. For more interviews like this, visit Proactive’s YouTube channel. Don’t forget to give the video a like, subscribe to the channel and enable notifications for future content. #CleanSpaceHoldings #IndustrialSafety #RespiratoryProtection #PAPR #WorkplaceSafety #OccupationalHealth #ASXStocks #HealthTech #EBITDA #MiningSafety #InfrastructureSafety #ProactiveInvestors

Proactive - Interviews for investors

Chesnara CEO discusses strong 2024 results, dividend growth and M&A outlook

Chesnara PLC (LSE:CSN) CEO Steve Murray talked to Proactive's Stephen Gunnion about the company’s strong 2024 full-year results, highlighting robust cash generation and consistent dividend growth. Murray highlighted that Chesnara generated £60 million in cash over the year, providing strong dividend coverage and supporting its 20-year track record of uninterrupted dividend growth. The business also increased its overall value and maintained a strong solvency position. The interview also covered Chesnara’s acquisition strategy, with Murray detailing the second Canada Life deal, which delivered an uplift in economic value to £11 million—higher than the £8 million initially expected—off a £2 million consideration. He explained that Chesnara currently holds around £200 million in acquisition firepower, supported by a solvency capital ratio of 203%. Murray described the current M&A pipeline as “positive,” noting that a reduction in private equity competition is opening up new opportunities in the UK and Benelux. He also commented on broader macroeconomic conditions, noting that despite some volatility, Chesnara’s long-term outlook remains stable due to natural hedges and long-duration contracts. Looking ahead to 2025, Murray reiterated Chesnara’s confidence in maintaining dividend growth, underpinned by strong visibility on future cash flows well above required commitments. For more CEO interviews and investor insights, visit Proactive’s YouTube channel. Don’t forget to like the video, subscribe to our channel, and hit the notification bell so you never miss an update. #Chesnara #InsuranceStocks #DividendGrowth #MergersAndAcquisitions #CashGeneration #UKStocks #BeneluxMarkets #CanadaLifeDeal #FinancialResults #InvestorUpdates #ProactiveInvestors

Followers	60
Posts	5219
Boards Moderated	2
Alias Born	08/02/2011

Volume:	-
Day Range:
Bid:	4.88
Ask:	7.84
Last Trade Time:
Total Trades:

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

ALBT Detailed Quote

Recent ALBT News

More ALBT News

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Recent ALBT News

Go Ad-Free